Pharmacy-as-a-service is the operating model where regulated pharmacy operations (dispensing, prescribing, governance, pharmacovigilance) are consumed as infrastructure by patient-facing brands — rather than built and operated by every brand individually. The model has matured rapidly in UK telehealth since 2022 and now powers a meaningful share of the new brand launches. This piece is the operator's view of pharmacy-as-a-service in 2026.
What pharmacy-as-a-service actually is
Pharmacy-as-a-service (PaaS) for UK telehealth is the model where the regulated layer of a pharmacy operation — GPhC-registered dispensing, prescriber network, clinical governance, pharmacovigilance — is provided as managed infrastructure rather than built by every brand from scratch. The brand consumes the regulated capability via API, web portal, or integrated workflow. The brand operates patient-facing; the provider operates the regulated layer.
This is analogous to how cloud computing replaced data-centre builds, or how Stripe replaced bank-integration projects for payments. The same shift is happening in regulated UK pharmacy: a foundational capability that used to require months of build is now consumable as infrastructure.
Why the model has scaled so fast since 2022
Three things converged. First, white-label infrastructure platforms matured — early providers proved the model worked operationally and regulatorily. Second, capital efficiency became a higher priority for new healthcare brands as venture funding tightened — the 12-18 month build wasn't viable for many. Third, regulatory scrutiny increased, making the operational discipline of mature pharmacy operators more valuable than the brand-build cost.
Brands launched between 2022-2026 increasingly chose PaaS over build. The 12-18 month build is now the exception, not the default. PaaS has shifted from emerging model to default architecture for new UK telehealth brand launches.
The build-vs-PaaS economic case
Build economics: £600k-£1.5m capital expenditure for the regulated layer (pharmacy premises, superintendent recruitment, clinical workflow build, prescriber network, pharmacovigilance system), 12-18 months timeline, ongoing operational overhead. The pay-off comes at scale when the per-dispense cost of in-house operation falls below the per-dispense PaaS pricing.
PaaS economics: £80k-£250k launch cost (mostly brand, marketing, integration work), 8-12 weeks timeline, per-dispense variable cost replacing the build's fixed cost. The pay-off is faster launch, lower capital risk, and the ability to test product-market fit before committing to infrastructure. Most brands stay on PaaS for the first 2-4 years; some transition to in-house as scale matures the economics.
What PaaS does and doesn't cover
Typical PaaS scope: GPhC-registered dispensing, prescriber network supply, clinical workflow framework, pharmacovigilance capture, integrations with payment and identity providers, regulatory alignment documentation, ongoing operational support. The brand retains: patient acquisition, brand identity and design, patient relationship and ongoing engagement, marketing operations, CRM and CDP, support tooling integration, commercial decisions on category and pricing.
The brand-PaaS boundary is operationally clean when the PaaS provider does this well. The boundary becomes painful when the brand expects the PaaS to handle marketing, CRM, or patient engagement — which is brand work, not regulated infrastructure.
What to look for in a PaaS provider
Five criteria. 1) Regulatory standing: GPhC-registered with a named superintendent, MHRA-aligned, with documented inspection history. 2) Category coverage: cold-chain, controlled drugs, Specials, your category specifically. 3) Integration depth: REST API, signed webhooks, EHR integration where needed. 4) Pricing transparency: per-dispense visible line items, no hidden platform fees. 5) Exit terms: data portability and patient record handover are clear in the contract.
Vendors that score well on all five enable durable brand-building. Vendors that score poorly on exit terms create lock-in that becomes painful when the brand wants to evolve.
PExpo as pharmacy-as-a-service for UK telehealth
PExpo operates a PaaS model: GPhC-registered dispensing, UK prescriber network (medical doctors and pharmacist independent prescribers), clinical workflow framework, pharmacovigilance infrastructure, and integrations with the common telehealth ecosystem. Two operating models — clinic-friendly £0 platform fee model with per-request pricing, and white-label brand model with per-dispense pricing.
See our brand model page for the white-label PaaS option, our clinic model page for clinics adding online prescribing, our pricing page for the commercial structure, and our integrations page for the connected ecosystem.
The 12-18 month pharmacy build is now the exception, not the default. Pharmacy-as-a-service has shifted from emerging model to default architecture for new UK telehealth brand launches in 2026.
This is analogous to how cloud computing replaced data-centre builds. A foundational capability that used to require months of build is now consumable as infrastructure.
Pharmacy-as-a-service has reshaped how UK telehealth brands launch in 2026. The build-from-scratch route is now the exception; PaaS is the default. Brands consuming PaaS launch in 8-12 weeks with variable-cost economics rather than 12-18 months with capital-heavy infrastructure builds. Choose PaaS providers on regulatory standing, category coverage, integration depth, pricing transparency, and exit terms. See our brand model page for PExpo's PaaS offering or our pricing page for the commercial structure.
Frequently asked questions
Is pharmacy-as-a-service legal in the UK?
Yes — the model relies on GPhC-registered pharmacies providing dispensing under proper regulatory accountability. The brand operates patient-facing; the PaaS provider operates the regulated layer. The arrangement is fully compliant with UK pharmacy regulation when structured properly.
What happens to my patients if I leave a PaaS provider?
Depends on the exit terms in the contract. Patient records, prescription history, and continuity-of-care arrangements should be portable. Verify this in the contract before signing — it's the most overlooked clause in PaaS evaluation.
Does PExpo offer PaaS?
Yes — PExpo's brand model is exactly this. Integrated dispensing + prescribers + clinical workflow as consumable infrastructure for UK telehealth brands. See our brand model page.
